| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Natural product
Lavandoside functions as a moderate inhibitor of xanthine oxidase (XO). It also acts as an ABTS⁺ free radical scavenger, exerting its effects through direct radical neutralization. The compound's antioxidant and potential anti-inflammatory effects are attributed to the hydroxyl groups in its molecular structure. Lavandoside modulates inflammatory pathways, thereby reducing inflammation. The compound's targets include antioxidant pathways and xanthine oxidase activity, with its mechanism related to the hydroxyl groups in its molecular structure. It has also been noted to have antibacterial activity. |
|---|---|
| ln Vitro |
The new natural compound lavandoside with the structure ferulic acid 4-O-β-D-glucopyranoside was isolated by column chromatography over silica gel and polyamide from the extract of Lavandula spica flowers. The chemical structure of lavandoside was established using UV, NMR, and mass spectra and chemical transformations[1].
Lavandoside demonstrates moderate inhibition of xanthine oxidase (XO). In LPS-induced macrophages, it inhibits nitric oxide (NO) production with an IC₅₀ of 71.6 μM. The compound exhibits ABTS⁺ free radical scavenging activity, indicating its potential as a natural antioxidant. Its mechanism involves direct scavenging of free radicals and inhibition of XO activity. Lavandoside acts as a reducing agent, scavenging free radicals and reducing oxidative stress in cells. It also has potential anti-inflammatory effects through its modulation of xanthine oxidase activity, attributed to the hydroxyl groups within its structure. |
| ln Vivo |
No detailed in vivo studies have been reported for Lavandoside. Its biological activities have been primarily characterized through in vitro assays, and no animal model data are currently available in the published literature. The compound is isolated from lavender and can be used in the development of natural antioxidants and in research on oxidative stress-related diseases and inflammation-related diseases.
|
| Enzyme Assay |
Lavandoside's xanthine oxidase inhibitory activity can be assessed using a standard spectrophotometric assay measuring uric acid production from xanthine substrate. ABTS⁺ radical scavenging activity is evaluated using the ABTS decolorization assay, where the compound's ability to reduce the ABTS radical cation is measured spectrophotometrically at 734 nm. NO inhibition is assessed in LPS-stimulated macrophage cultures using the Griess assay. The antioxidant power of Lavandoside has been evaluated by HPLC-ABTS⁺, TEAC and ORAC assays. The compound's antioxidant activity has been demonstrated through these established biochemical assays.
|
| Cell Assay |
The cellular activity of Lavandoside is evaluated in mouse RAW264.7 macrophages stimulated with lipopolysaccharide (LPS) to induce nitric oxide production. Cells are treated with Lavandoside for 24 hours, after which NO levels in the culture supernatant are measured using the Griess assay. The compound shows an IC₅₀ of 71.6 μM for inhibiting LPS-induced NO production. This assay demonstrates the compound's anti-inflammatory activity in mouse RAW264.7 cells. The cellular model is used to assess the compound's ability to modulate inflammatory responses through the inhibition of nitric oxide production.
|
| Animal Protocol |
No in vivo animal experimental protocols have been documented for Lavandoside. As a natural product research compound, its primary evaluation has been limited to cell-based and biochemical assays. The compound is used in the development of natural antioxidants and in research on oxidative stress-related diseases and inflammation-related diseases, but these applications are primarily studied in vitro.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Lavandoside have not been reported. As a glycoside, it may undergo deglycosylation in the gastrointestinal tract, potentially affecting its oral bioavailability and systemic exposure. The compound's pharmacokinetic properties have not been characterized in the published literature.
|
| Toxicity/Toxicokinetics |
No toxicity data have been reported for Lavandoside. As a naturally occurring phenolic glycoside found in lavender, it is generally considered to have a favorable safety profile, though systematic toxicological evaluation has not been performed. The compound is classified as a natural product with antioxidant and anti-inflammatory potential.
|
| References | |
| Additional Infomation |
4-O-β-D-glucosyl-trans-ferulic acid is a methoxycinnamic acid derivative of ferulic acid, in which the phenolic hydroxyl group at position 4 is converted to β-D-glucosinolate. It is a plant metabolite. It is a β-D-glucosinolate, monomethoxybenzene, monosaccharide derivative, and methoxycinnamic acid. It is functionally related to ferulic acid. It is the conjugate acid of 4-O-β-D-glucosyl-trans-ferulic acid. (E)-4-hydroxy-3-methoxycinnamic acid 4-O-|AD-glucopyranoside has been reported in tea (Camellia sinensis), potato (Solanum tuberosum), and other organisms with relevant data.
Lavandoside is a research compound not approved for clinical use. It is classified as a natural product with antioxidant and anti-inflammatory potential, making it of interest for studies on oxidative stress, inflammation, and the development of natural antioxidants. No clinical trials have been reported for this compound. The compound is isolated from lavender and Helianthemum ruficomum and has been identified as one of several antioxidant compounds from these sources. It is used for research purposes only and is not intended for therapeutic use. |
| Molecular Formula |
C16H20O9
|
|---|---|
| Molecular Weight |
356.32
|
| Exact Mass |
356.11
|
| CAS # |
117405-51-3
|
| PubChem CID |
13916049
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.0 g/cm3
|
| Boiling Point |
642.0±0.0 °C at 760 mmHg
|
| Flash Point |
235.8±0.0 °C
|
| Vapour Pressure |
0.0±0.0 mmHg at 25°C
|
| Index of Refraction |
1.650
|
| LogP |
-0.79
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=CC(\C=C\C(O)=O)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
|
| InChi Key |
IEMIRSXOYFWPFD-BJGSYIFTSA-N
|
| InChi Code |
InChI=1S/C16H20O9/c1-23-10-6-8(3-5-12(18)19)2-4-9(10)24-16-15(22)14(21)13(20)11(7-17)25-16/h2-6,11,13-17,20-22H,7H2,1H3,(H,18,19)/b5-3+/t11-,13-,14+,15-,16-/m1/s1
|
| Chemical Name |
(E)-3-[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoic acid
|
| Synonyms |
Lavandoside; 2-Propenoic acid, 3-[4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl]-, (2E)-; (E)-4-Hydroxy-3-methoxycinnamic acid 4-O-; A-D-glucopyranoside; (2E)-3-[4-(beta-D-Glucopyranosyloxy)-3-methoxyphenyl]-2-propenoic acid; (E)-3-[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoic acid; Ferulic acid 4-glucoside;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (140.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8065 mL | 14.0323 mL | 28.0647 mL | |
| 5 mM | 0.5613 mL | 2.8065 mL | 5.6129 mL | |
| 10 mM | 0.2806 mL | 1.4032 mL | 2.8065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA